Advancing Accessible Gene Therapy for Sickle Cell Disease – San Rocco Therapeutics Gets Closer

The 2024 American Society of Hematology (ASH) meeting showcased significant milestones in gene therapy for Sickle Cell Disease (SCD), honoring two pioneers in the field, Dr. Stuart Orkin and Dr. John Tisdale, with the prestigious Ernest Beutler Lecture and Prize. Their groundbreaking work has transformed the treatment landscape for SCD, offering hope to patients through innovative gene editing and replacement therapies.